Navigation Links
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Date:12/5/2012

JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23rd Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at 2:45 PM Eastern Time in New York and provide a business overview and update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications

'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 NSHOA Cancer Center ... today announced positive, top-line results from its recently ... efficacy and safety of the Company,s 5-HT 3 ... (granisetron injection, extended release) as part of a ... 1 ) receptor antagonist fosaprepitant and the IV ...
(Date:6/1/2015)... , June 1, 2015 Researchers from ... Case Western Reserve University School of Medicine will present ... a potential novel combination treatment for cancer patients with ... mutations in small cell lung cancer (SCLC), at the ... Annual Meeting in Chicago . ...
(Date:6/1/2015)... 1, 2015   OTC Markets Group Inc. ... Connected financial marketplaces for 10,000 U.S. and global ... San Diego -based biopharmaceutical company, on its ... only public venture market for entrepreneurial and development ... "We,re happy to congratulate ...
Breaking Medicine Technology:New cancer therapy study results - MAGIC Trial 2UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 2UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 3OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
(Date:6/2/2015)... FDA approved Orlistat for weight loss ... satisfactory doctor consultation. The less potent, over-the-counter version of Orlistat, ... has the longest track record as an FDA approved weight ... down fats in foods, Orlistat treatment prevents the body from ... be excreted through feces. , The most common ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Thermi, ... technology company has successfully transitioned into its new ... due to the company’s continued rapid worldwide expansion ... comprised of over 25 Thermi employees, including those ... development teams. , “As one of the fastest ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 While the ... adaptions of comic books, comic books themselves are stepping ... Comics Uniting Nations plans to produce educational comics in ... Global Goals for Sustainable Development - an international effort ... poverty, hunger, health, education, sustainable energy, inequality, climate change ...
(Date:6/2/2015)... SB 277 (CA Legislature, bit.ly/1Q0P8OY) will require ... public or private school. SB277 cleared three Senate policy ... Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). It passed ... “We believe that this bill affects the education of ... will (the) affect public health of California.. It is ...
(Date:6/2/2015)... “We want men to realize the importance of protecting ... Phillips, owner of SunGrubbies.com, “that is why we offer ... that work well for outdoor activities.” , The effects of ... can take up to thirty years to develop. The ... cancer to occur. That is why the simple act ...
Breaking Medicine News(10 mins):Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2
... Md., Aug. 12 The third annual Psoriasis Cure Now ... a theme of helping psoriasis patients connect with one another. ... patients to resist the social isolation that often results from ... with psoriasis and psoriatic arthritis to provide mutual support and ...
... French . , Montreal, August 12, 2009 Sounds ... according to a new Canadian study. In the online edition of ... PNAS ), scientists from the Universit de Montral and the Montreal ... in the brain allows people to distinguish between different types of ...
... ... of device, new trials , ... San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage ... permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials ...
... , , Milestone shows ... shows how much the culture has changed when reporting medical events , ... Safety Authority has collected over one million reports from Pennsylvania healthcare facilities ... events that did not cause harm to the patient. , , ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that ... correct the ownership of its intellectual property (IP) rights. ... five (5) issued patents, HTDS finds that the Company ...
... ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: VSCP ... financial results for the quarter and six months ended June 30, 2009. ... Revenues for the second quarter of 2009 increased 47% to $2.5 million, compared ... Gross profit for the second quarter of 2009 increased 96% to $1.4 ...
Cached Medicine News:Health News:Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 2Health News:Human mind: Sound and vision wired through same 'black box' 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 2Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 4Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 2Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 3Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 2Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 3Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 5Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 6Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 7Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 8Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 9
... of the Criterion precast gel system, allows you ... a single run. Criterion gels are wider and ... mini gel. They accommodate Bio-Rad's 11 cm ReadyStrip ... of separation and speed in 2-D electrophoretic applications. ...
... Mini-Vertical Gel System simplifies the process of separating ... It is able to run four gels at ... maximize utility and throughput, the 120 mini-vertical runs ... (W x L) at one time. The 120 ...
... High-Throughput (HTP) Protein Electrophoresis ... integrated pre-cast gel system ... protein analysis. It consists ... E-Base™ integrated power device, ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
Medicine Products: